Eledon Pharmaceuticals, Inc. — Director's Dealing 2014

Oct 17, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tokai Pharmaceuticals Inc (TKAI)
CIK: 0001404281
Period of Report: 2014-10-15

Reporting Person: Morrison Jodie Pope (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-10-15	Stock Option (right to buy)	$13.25	A	134134	Acquired	2024-10-15	Common Stock (134134)	Direct

Footnotes

F1: This option vests with respect to 12.5% of the shares underlying the option on May 1, 2015 and an additional 2.0833% monthly thereafter through November 1, 2018.